At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ACXP Acurx Pharmaceuticals, LLC*
Trading 01-16 10:09:24 EST
2.72
+0.03
+1.12%
High2.80
Low2.66
Vol6.91K
Open2.68
D1 Closing2.69
Amplitude5.20%
Mkt Cap6.39M
Tradable Cap6.04M
Total Shares2.35M
T/O18.61K
T/O Rate0.31%
Tradable Shares2.22M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Acurx Pharmaceuticals and Leiden University Medical Center Secure $375,000 Health~Holland Grant for Antibiotic Research
Acurx Pharmaceuticals Receives Positive EMA Opinion on Pediatric Investigation Plan for Ibezapolstat in Children with C. difficile Infection, Advancing Toward Phase 3 Trials
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.